ObjectivesAfter decades of unsuccessful efforts in inhibiting KRAS, promising clinical data targeting the mutation subtype G12C emerge. Since little is known about outcome with standard treatment patients mutated non-small cell lung cancer (NSCLC), we analyzed a large, representative, real-world cohort from Germany.Patients and methodsA total 1039 advanced KRAS-mutant or -wildtype NSCLC without...

PURPOSE The PETACC 6 trial investigates whether the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal cancer. METHODS Between November 2008 September 2011, patients with adenocarcinoma within 12 cm from anal verge, T3/4 and/or node positive, were randomly assigned 5 weeks (45-5...